Description
Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analogue. Rather than supplying growth hormone directly, it stimulates the pituitary gland to release more of the body’s own growth hormone, which in turn increases levels of insulin-like growth factor-1 (IGF-1).
Tesamorelin is marketed under the brand name Egrifta and is approved in the United States for reducing excess visceral (deep abdominal) fat in adults with HIV-associated lipodystrophy. It is not approved as a general weight-loss treatment.
How does it work?
Tesamorelin works by:
- 🧠 Stimulating natural growth hormone release.
- 📈 Increasing IGF-1 levels.
- 🔥 Promoting the breakdown of visceral (deep abdominal) fat.
- 💪 Supporting changes in body composition through the growth hormone pathway.
Potential Benefits
Clinical research has shown that Tesamorelin may:
- ✔️ Reduce visceral (deep belly) fat.
- ✔️ Improve body composition.
- ✔️ Reduce liver fat in some people with HIV-associated fatty liver disease.
- ✔️ Increase endogenous growth hormone and IGF-1 levels.
- ✔️ Improve certain metabolic markers in the populations studied.
What it’s being studied for
Researchers are also investigating Tesamorelin for possible roles in:
- Metabolic health
- Non-alcoholic fatty liver disease (NAFLD)
- Healthy ageing
- Cognitive function
- Body composition
These uses remain investigational or off-label and are not established indications.
Common Side Effects
Reported side effects include:
- Injection-site reactions
- Joint or muscle pain
- Swelling or fluid retention
- Increased IGF-1 levels
- Possible increases in blood glucose
- Headache
Summary
Tesamorelin is one of the best-studied peptides affecting the growth hormone pathway. It is unique because it has an FDA-approved medical use for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy, with multiple clinical trials supporting that indication. While it is also discussed for broader body-composition and metabolic goals, those uses have not been established to the same standard of evidence.
Reviews
There are no reviews yet.